Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-2280-401 trial for clearance of high-risk HPV
PACTR202408538482330Phase 1Recruiting
- Sponsor
- Antiva Biosciences
- Start
- Mar 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1 trial of ABI-2280 in human papillomavirus infection, sponsored by Antiva Biosciences. Started Mar 2024; status: recruiting.
02
Drugs
ABI-2280
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on PACTR202408538482330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408538482330.